Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: outside layer (24), covering (409), varnish (16), glaze (4), shell (12)

Dacomitinib

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DACOMITINIB Regimen • NSCLC - Dacomitinib Indication Dacomitinib for untreated EGFR-positive non-small-cell
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Dacomitinib.pdf

Darolutamide

Description: Chemotherapy Protocol PROSTATE CANCER DAROLUTAMIDE Regimen • Prostate - Darolutamide Indication • Darolutamide is recommended where the; - patient has a proven histological or cytological
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Darolutamide.pdf

Ponatinib

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Ponatinib All licensed indications are not funded therefore an application for funding is required before prescribing
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Ponatinib.pdf

Apalutamide v1

Description: Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostate cancer as defined by recent imaging
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

Capecitabine-TrastuzumabIV-Tucatinib

Description: Chemotherapy Protocol BREAST CANCER Capecitabine–Trastuzumab (IV)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (IV)-Tucatinib Indication t • Treatment of over-expressed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-IV-Tucatinib.pdf

Capecitabine-Trastuzumab-SC-Tucatinib

Description: Chemotherapy Protocol BREAST CANCER Capecitabine– Trastuzumab (SC)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (SC)-Tucatinib Indication • Treatment of over-expressed HER2
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-SC-Tucatinib.pdf

VR-RituximabVenetoclax Cycle_2 Onwards

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) (Cycle 2 onwards) Regimen • CLL – VR Rituximab Venetoclax (high risk) Cycle
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

Enzalutamide

Description: Chemotherapy Protocol PROSTATE ENZALUTAMIDE Regimen • Prostate-Enzalutamide Indication • Enzalutamide is recommended within its marketing authorisation as an option for treating metastatic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Enzalutamide.pdf

VenetoclaxLow

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (low risk) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf

Chlorambucil_7day

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (7 day) There are several versions of this protocol each using a different dose or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-7day.pdf

1 to 10 of 68

Previous 1 2 3 4 5 … Next